Avelumab is administered intravenously, usually over a period of one hour. The typical dosing schedule is every two weeks. The exact dosage and schedule can vary depending on factors such as the type of cancer being treated, the patient's overall health, and how well they tolerate the treatment. It is usually given in a clinical setting under the supervision of a healthcare provider.
